Session Abstract – PMWC 2022 Silicon Valley


  • Dismantling Barriers to Biomarker Testing Through Collaboration (PANEL)
    Session Chair: Omar Perez, AstraZeneca - Nikki Martin, LUNGevity
    - Jenn Higgins, Guardant Health
    - Kamala Maddali, Deep Lens
    - Dan Rhodes, Strata Oncology
  • Health Systems Perspective: Leveraging Real-world Evidence to Improve Patient Care (PANEL)
    Session Chair: Anna Berry, Syapse
    - Mary Walters, Aurora Health
    - Haythem Y Ali, Henry Ford Health System
  • Comprehensive Profiling: Combination of Tissue and Plasma Biomarker Strategies
    Session Chair: Maggie Rougier-Chapman, Personal Genome Diagnostics (PGDx)
    - Cynthia Pointer, Genapsys
    - Ravi Kolhe, Augusta University
    - Stephen Miller, Blueprint Medicines
  • Immuno-oncology Biomarkers for Predicting Drug Efficacy
    Session Chair: Padma Sundar, Oncocyte
    - Paul Billings, Natera
    - Daniel Rhodes, Strata Oncology
  • Reimagining Oncology - Closing the Gaps between Science and Clinic (PANEL)
    Session Chair: Christian Wolfrum, Siemens Healthineers
    - Ben Gonzales, Biognosys AG
    - Debanti Sengupta, Varian
    - Rangarajan Sampath, Siemens Healthineers
    - Steven Artandi, Stanford
  • Challenges to Implementing Precision Oncology in the Community Setting (PANEL)
    Session Chair: Jerry Mitchell, Foundation Medicine
    - Erika Brown, One Cancer Place
    - Lee Schwartzberg, OneOncology
    - Vivian Lee, Patient Advocate
  • Community Hospitals Reimbursement Landscape and Modeling (PANEL)
    Session Chair: Brady Davis, Canexia Health
    - Julie Eggington, CGI (Center for Genomic Interpretation)
    - Jennifer Strickland-Reddy, Sutter Health

 Session Chair Profile

Ph.D., Head of Medical Diagnostics, US Medical Affairs Oncology, AstraZeneca

Biography
Dr. Omar Perez has over 17 years designing, deploying, and leading high-visibility oncology initiatives supporting global companion diagnostic developments, strategic partnerships and commercialization opportunities. Before joining AstraZeneca, he oversaw the global CDx developments for the GSK oncology portfolio, leading to diagnostic products for niraparib and dostarlimab. During his time at Pfizer, he led global CDx activities supporting the drug approvals of crizotinib, lorlatinib, dacomitinib talazoparib and inotuzomab. Notably, he led the first FDA approved NGS product for multiple targeted agents and helped establish the Center for Precision Medicine in LATAM to support Pfizer oncology products. Dr. Perez’s background includes roles in biotech and diagnostic companies, including co-founding Nodality, a diagnostic company focused on hematological malignancies. He is an inventor of the multiparametric phospho-proteomic flow technologies and an author of 37 publications and 35 patents.


 Session Chair Profile

M.D., VP, Molecular, Pathology and Genomics, Syapse

Biography
Dr. Anna Berry i works in partnership with Syapse’s functional leaders to support product and service development, serves as a subject matter expert to Syapse’s customers, participates in joint-authored research and publications, and advances Syapse’s thought leadership efforts in the area of real-world evidence. Prior to her recent move to Syapse, she served for 6 years as the Deputy Director for Molecular Pathology and Genomics, and as the Scientific Director for the Personalized Medicine Program at the Swedish Cancer Institute in Seattle, and concurrently served as Director of Genomics Programs at CellNetix Pathology and Laboratories. Dr. Berry has focused professionally on genomics education and personalized medicine. In these roles, she has given numerous presentations, nationally and internationally, and has served on multiple task forces and committees for several professional organizations and coalitions, spanning Pathology and Oncology focused efforts.


 Session Chair Profile

SVP, Head of Marketing & Commercial Strategy, Personal Genome Diagnostics (PGDx)

Biography
As Senior Vice President of Marketing & Commercial Strategy, Maggie Rougier-Chapman leads the company’s marketing and commercial planning efforts to drive global growth and patient impact by creating broader awareness and accelerating customer adoption of the PGDx elio™ product line. Ms. Rougier-Chapman is a strategic leader with deep domain expertise spanning the diagnostics, genomics and life science sectors. Over the past two decades, she has been delivering successful business growth for both large multinational and rapidly scaling companies through commercialization of genomic solutions for clinical and research use. Prior to PGDx, Ms. Rougier-Chapman served as Head, Oncology Product Management & Strategy at Invitae, having joined Invitae through the acquisition of ArcherDX, where she served as Executive Vice President, Commercial Operations. In this role, Ms. Rougier-Chapman prepared ArcherDX for a successful exit and integration by reshaping the company’s product management, marketing & sales operations to support revenue growth, companion diagnostic (CDx) program expansions and global product launches of NGS-based in vitro diagnostics for therapy selection and monitoring. Prior to that, she served as Vice President, Global Marketing, at Bionano Genomics, Inc., where she led marketing, product management, and branding for the company’s optical genome mapping technology. Ms. Rougier-Chapman also held sales & marketing leadership roles at Agilent Technologies’ Diagnostics & Genomics Division, as well as various commercial roles at Advanced Cell Diagnostics, Cogenics, Ribonomics, Incyte Genomics, and Stratagene. She holds an M.S. in Molecular Cancer Biology and a B.S. in Biology from Duke University.


 Session Chair Profile

Ph.D., Head New Business Development & Planning, Siemens Healthineers

Biography
Christian is responsible for driving business development and incubation in adjacent fields and white spaces at Siemens Healthineers. Christian and his team evaluate opportunities, trigger investments in start-ups, and drive partnership projects – with a particular focus on the field of precision medicine. Christian also serves on the board of associations and start-up companies focusing on precision medicine. Christian brings more than 15 years of experience in new business development and has successfully incubated a variety of new products, developed strategies for leading global companies, and is the (co)-inventor of assorted patent families. He is driven by his passion to bridge the chasm between innovative ideas and the commercialization of new technologies.

Talk
Reimagining Oncology - Closing the Gaps between Science and Clinic
Today we see major gaps in oncology care delivery when it comes to transferring innovation from scientific discovery into clinical practice. Together with experienced industry professionals we will discuss persisting gaps along the oncology patient journey and how they can be addressed by making use of emerging trends.


 Session Chair Profile

M.D., Director Field Medical Oncology, Foundation Medicine

Biography
Jerry Mitchell has a current focus on national education and support for oncologists around comprehensive genomic profiling with an attention to therapeutic applications. Prior to joining Foundation Medicine he was a practicing oncologist at the Mark H. Zangmeister Center in Columbus, OH. He is Board Certified in Internal Medicine, Oncology, Hematology, and Hospice and Palliative Care. He received his MD from the University of North Carolina at Chapel Hill and his MBA from the Kelley School of Business at Indiana University with an emphasis on corporate strategy.


 Session Chair Profile

SVP Business Development & Strategy, Canexia Health

Biography
Brady heads business development, market development and strategy for Canexia Health where we make high-quality cancer genomic information accessible and affordable with our clinically validated assays, informatics, and support. As part of the Executive Management Team, Brady's responsibilities include developing and managing all Business Development and Market Development activities as well as Partnerships and Joint Ventures. Brady works closely with the CEO to set the companies 3-year strategy and keep the company on track to execute to plan. Prior to Canexia Health Brady lead strategy, market development and marketing for DNAnexus. Brady was responsible for building strategic partnerships with both technology and services-based organizations and as a member of the Executive Team is responsible for setting corporate strategy, running corporate development and innovation activities. Prior to DNAnexus Brady was head of strategy and market development for Illumina with a special focus on Informatics.


 Session Chair Profile

M.P.H., Chief Commercial Officer, Oncocyte

Biography
Padma has extensive experience in commercializing and driving market leadership for molecular diagnostics at Roche Sequencing, Guardant Health, and Affymetrix. At Oncocyte, Padma commercialized and secured positive Medicare coverage for DetermaRx, the 1st and only test for predicting risk of recurrence in early-stage lung cancer. Since its launch in 2020, the test has been adopted by over 300 physicians in the United States. She is leading the commercialization and reimbursement for the company’s pan-cancer diagnostic tests for immunotherapy selection and blood-based monitoring.


 Speaker Profile

Director, Precision Medicine Initiatives, LUNGevity Foundation

Biography
Nikki focuses on accelerating access to precision medicine, especially biomarker testing, for lung cancer patients. Nikki came into patient advocacy from multiple roles at pharmaceutical and diagnostic companies including Genentech, Novartis, and Grifols where she collaborated with patient advocacy groups across different cancer types and other diseases in the US and around the world. This has given her a great vantage point to see the true value of patient advocacy-led multi-stakeholder efforts for jump-starting conversations. She believes that patient advocacy organizations play an essential role in convening different players from government to providers, payers, and industry and leading or contributing to critical work that has long lasting impact on patient care.


 Speaker Profile

Vice President, Public Affairs, Guardant Health

Biography
Jenn Higgins is responsible for leading and directing the overall government affairs, patient advocacy, public policy, and corporate communications functions for Guardant Health (NASDAQ: GH). As a veteran of Washington DC, Jenn serves as the company’s point of contact with Congress and the Administration, actively working with key health care stakeholders to help shape public debate around issues that matter to Guardant Health. Jenn has spent the past twenty years using her tenacity and policy knowledge to help corporate executives navigate a constantly changing legislative and regulatory landscape. As a lobbyist, Jenn has represented a wide variety of Fortune 500 health care companies before Congress and the Administration, serving as Partner with two prominent lobbying firms. She also worked as an analyst and Special Assistant at the Centers for Medicare & Medicaid Services, with an emphasis on Medicare policy. Jenn attended Davidson College where she received a B.A. in Medical Economics and Ethics.


 Speaker Profile

Ph.D., President, Health Collaborations

Biography
Dr. Kamala Maddali has extensive experience as a strategy leader for precision medicine at Fortune 100 and 500 companies like Merck and Co, Quintiles, Quest Diagnostics implementing corporate strategic initiatives to foster positive growth of the company in precision medicine. Her vision is to ensure that the patient’s voice is heard, and her goal is to help patients with powerful tools from science and innovation for improving global community health. Dr. Maddali is the author of "Becoming a Kamala" a memoir focused on her unique journey which unveils her various avatars in her pursuit towards becoming a better human, woman, and a rare disease patient. In 2021, Dr. Kamala Maddali has been awarded Pharma Voice 2021 Top 100 Most Inspiring Leaders in the Healthcare Industry. The award is prestigious and honorable recognition to be a part of a select group of leaders, mentors, and visionaries in the Life Sciences who inspire change.


 Speaker Profile

Ph.D., Co-founder and CEO, Strata Oncology

Biography
Dan Rhodes is a scientist and entrepreneur focused on precision medicine in oncology. He co-founded Strata Oncology, a venture-backed precision oncology company committed to acceler-ating the impact of precision medicine for patients with cancer. Previously, Dan was VP of Oncology for Thermo Fisher Scientific (Life Technologies) where he oversaw the development of cancer sequencing products and pharma companion diagnostic partnerships. Prior to that, Dan was co-founder and CEO of Compendia Bioscience, a University of Michigan spin-off formed to commercialize his thesis project, Oncomine, a cancer genome data-mining platform. Dan has co-authored 40+ publications and is a co-inventor on 10 patents, including the discov-ery of gene fusions as a genetic cause of prostate cancer. In 2019, Dan was named Ernst & Young Entrepreneur of the Year for the Midwest region. Dan served on the oversight committee for the Michigan Translational Research and Commercialization (MTRAC) Program and on multi-ple advisory boards.


 Speaker Profile

M.B.A., Head of Sales, Biognosys

Biography
Ben Gonzales serves as the leader of Business Development efforts for Biognosys in North America. With a history in mass spectrometry and proteomics Ben has been able to successfully guide the team in support of solutions in Precision Medicine and Unbiased Discovery.


 Speaker Profile

Ph.D., Sr. External Innovation Director, Varian Medical Systems

Biography
Debanti leads due diligence activities on commercial opportunities of interest, and manages an international portfolio of oncology-focused industry-academic research projects.


 Speaker Profile

Ph.D., Senior Vice President and Head, Center for Innovation in Diagnostics, Siemens Healthineers

Biography
Dr. Rangarajan Sampath is Senior Vice President and Head of Center for Innovation in Diagnostics at Siemens Healthineers, where he leads Innovation and new product development in the areas of oncology, neurology and infectious diseases. CID’s focus is to drive disruptive next generation innovation, development and commercialization of in-vitro diagnostics, automation and digital health solutions. Prior to this, Dr. Sampath was Chief Scientific Officer at Foundation for Innovative New Diagnostics (FIND), a Geneva-based non-profit organization (NGO) focused on bringing cutting edge diagnostics to low- and middle- income countries. Dr. Sampath headed FIND’s research and development organization, leading its innovation, product development and disease programs. During the COVID-19 pandemic, he led a team of researchers to set up an evaluation framework to provide independent assessment of commercially available assays to aid procurement and country prioritization decisions. He also represented FIND as a Working Group member in the Access to COVID Tools -Accelerator Diagnostics (ACT-A Dx) Partnership, co-convened by FIND and the Global Fund. From 1997-2017, Dr. Sampath served as a Volwiler Senior Research Fellow and Senior Director of R&D for the Ibis Division of Abbott. He led Ibis’ R&D efforts in infectious disease diagnostics, antimicrobial resistance diagnostics and surveillance, and was responsible for applications development, validation, data analysis and reporting for the Ibis PCR/ESI-MS based IRIDICA platform. Dr. Sampath was the co-founder of Ibis Biosciences, Inc. and a co-inventor of the IRIDICA (CE-IVD) infectious disease diagnostics platform. Dr. Sampath is a recognized leader in the field, with over 100 publications and over 40 issued patents in infectious disease diagnostics. He was an invited participant at the White House National Forum on Antibiotic Stewardship and was an active member of the AdvamedDx Industry Forum for the global commitment on developing diagnostic tests to fight AMR. He has been an invited speaker at many public forums such as at the Institute of Medicine, Infectious Diseases Society of America (IDSA) and Parenteral Drug Association (PDA). He was a key member of an FDA/PDA task force involved in defining the future of viral screening for cell substrates. Dr. Sampath most recently served for a 3-year term as a member of the Diagnostics Committee for IDSA. His research interests include sepsis, antimicrobial strategy development, pathogen discovery, fevers of unknown origin, tropical diseases, epidemiological surveillance and biothreat detection.

Talk
Improving Cancer Outcomes through Early Precision Diagnostics
Exponentially growing knowledge and precise technologies provide great opportunity for individualization of therapeutic intervention. Scalable precision diagnostics will improve disease outcomes through early detection and monitoring in cancer patients. Digital integration of data is key to achieving both. This talk will focus on combining “omics” data with imaging for comprehensive cancer care.


 Speaker Profile

M.D., Ph.D., Director, Stanford Cancer Institute, Stanford University

Biography
Dr. Steven Artandi is the Director of the Stanford Cancer Institute and Professor of Medicine and Biochemistry at Stanford University. He also serves as the inaugural Senior Associate Dean for Cancer Programs for Stanford School of Medicine and the Chief Cancer Officer for Stanford Health Care. He received his undergraduate degree from Princeton University, and MD and PhD degrees from Columbia University. He trained in Internal Medicine at Massachusetts General Hospital and in Oncology at Dana-Farber Cancer Institute before joining the Stanford faculty in 2000. Dr. Artandi is an oncologist and cancer biologist whose research work has focused on the role played by the enzyme telomerase in cancer, aging and stem cell function.


 Speaker Profile

M.D., FACP, Medical Director, West Cancer Center; Chief Medical Officer, OneOncology

Biography
Lee S. Schwartzberg, MD, FACP, is medical director of the West Cancer Center and Research Institute, Professor of medicine at The University of Tennessee Health Science Center in Memphis, and served as the Chief of the Division of Hematology/Oncology in the Department of Medicine from 2012-2018. In 2019 he became founding Chief Medical Officer at OneOncology, a national oncology practice management and services organization. He maintains an active medical oncology practice. In his research career, he has published more than 260 manuscripts on breast cancer, precision oncology and supportive care and received an ASCO clinical trials participation award. Dr. Schwartzberg previously served on the National Comprehensive Cancer Network Board of Directors, its Guideline Steering Committee, and the Breast Cancer Guideline Panel, among others. He is past founding chairman of the Association of Community Cancer Centers Immuno-Oncology Institute and serves as the editor-in-chief of the Elsevier website PracticeUpdate Oncology.


 Speaker Profile

Ph.D., Co-founder and CEO, CGI (Center for Genomic Interpretation)

Biography
Dr. Eggington advises policy makers on precision medicine, and is a contributing member of numerous committees, including the CDC/FDA/CMS Next Generation Sequencing Best Practices Forum. She oversees CGI's ELEVATEGENETICS initiative, which helps health insurance payers identify the more accurate and clinically efficacious genetic and genomic tests. Dr. Eggington directed programs at Myriad Genetics, Courtagen, and 23andMe prior to co-founding a genetic diagnostics consultancy company in 2016. The need for a disruptive nonprofit organization became clear through this consulting work, and Dr. Eggington co-founded CGI in 2017. She was a 2019 Sego Award winner for Utah women co-founders/CEOs in Innovation in Technology. Dr. Eggington also holds an affiliate faculty position at Brigham Young University.


 Speaker Profile

Patient/Research Advocate, UCSF

Biography
A trained research advocate, Vivian collaborates with scientific and clinical investigators at institutions worldwide to provide patient perspective to the design and execution of breast cancer research projects.


 Speaker Profile

Chief WayFinder, One Cancer Place

Biography
Creator/Builder ONE CANCER PLACE - the first stop for patients. Leading Patient KOL addresses urgent need: education and molecular testing of the newly-dx'd patients. EDUCATION, NAVIGATION, LEGISLATION, COMMUNITY.


 Speaker Profile

PHARM.D., Co-Director Oncology Precision Medicine, Advocate Aurora Health

Biography
Mary Walters is a clinical pharmacist at Advocate Aurora Health in Milwaukee who serves as a co-director of the Oncology Precision Medicine program, oncology pharmacy practice counsel chair, and Aurora specialty pharmacy oncology specialist. Walters obtained her Bachelor of Arts degree in chemistry with a biochemistry concentration at Saint Catherine University in Saint Paul, Minnesota in 2012 and her Doctor of Pharmacy degree from the University of Minnesota, Twin Cities in 2016. Walters trained as a PGY-1 pharmacy resident at the Level 1 Trauma Center, North Memorial Medical Center, in Robbinsdale, Minnesota where she developed a ketamine pain management protocol and an interest in oncology. For her PGY-2, Walters specialized in oncology at Advocate Aurora, optimizing pharmacy transition of care for patients with cancer. Walters remained at Advocate Aurora and has served as a clinical pharmacist in the Milwaukee metro area cancer clinics and inpatient services for three years.


 Speaker Profile

M.D., Senior Oncologist, Henry Ford Health System

Biography
Dr. Ali’s Clinical and academic interests are in discovering the impact of ethnic disparities in the biology of different neoplastic processes. Dr. Ali became interested in keloid disorder as it is another disorder where ethnicity plays a significant role in the biology and clinical presentation of the disease process. Dr. Ali is an active participant in national and international trials through his active participation with the national cancer institute cooperative group research mechanism and numerous industry-supported clinical trials. He is an active member of both the Southwest Oncology Group (SWOG) and NRG Oncology. He is bringing all his clinical trial expertise to design and conduct trials that we are planning to conduct in the very near future in keloid patients. Dr. Ali is an active member of the American Medical Association, American Society of Clinical Oncology, European society of clinical oncology, and the Michigan Society of Hematology and Oncology.


 Speaker Profile

Senior Vice President of Global Market Access & Policy, Genapsys Inc

Biography
Cynthia Pointer is the Senior Vice President of Global Market Access & Policy at Genapsys Inc. In this role, she is responsible for market access strategy development, product adoption, and execution of global market advocacy for Genapsys. Cynthia brings over 25 years of immense commercial experience to Genapsys. Her expertise includes global reimbursement, health policy, government affairs, and CMS account management. Cynthia is a recognized leader in managing multinational cross-functional teams and resources to implement strategic reimbursement initiatives specializing in the therapeutic areas of oncology, transplant, age-related macular degeneration, human genetic therapies, pain, and molecular diagnostics. Cynthia has served in major leadership positions in both the pharmaceutical and diagnostic space. Prior to joining Genapsys, Cynthia was the Senior Vice President of Global Market Access at ArcherDX (acquired by Invitae in 2020), a global leader in comprehensive cancer genetics and precision oncology. She has also held various leadership positions at Recro Pharma, Genzyme, Regeneron Pharmaceuticals, and Millennium Pharmaceuticals. Cynthia is uniquely qualified to achieve Genapsys’ mission of transforming research and diagnostics with an affordable, scalable genomic sequencing ecosystem. Cynthia holds a Master of Arts degree specializing in clinical psychology from Marymount University. Cynthia was also voted as one of the top 25 most influential women in biotech during 2020.


 Speaker Profile

M.D., Ph.D., Leon Henri Charbonnier Endowed Chair of Pathology, Augusta University

Biography
Dr. Ravindra Kolhe is a Leon Henri Charbonnier Endowed Chair of Pathology at Augusta University and is the inaugural Associate Dean for translation research at Medical College of Georgia. He also serves as the Associate Cancer Center Director for Genomics at the Georgia Cancer Center. Currently, Kolhe leads an NCI-designated translational pathology laboratory for MATCH testing which is focused on comprehensive genomic testing in oncology. He co-founded a consortium (SEQUOIA) of 40+ clinical laboratories across the globe for the democratization of NGS testing in oncology & successfully helped multiple labs to bring NGS testing in-house. He served on the Georgia Governor’s Task Force for COVID-19 and successfully led the COVID-19 screening program for the State of Georgia during the early Pandemic. Kolhe is also a co-founder of a COVID-19 Host Genome Structural Variation Consortium and coordinated a global network of researchers who are contributing to our collective knowledge on host genome response to the SARS-CoV-2 infection and COVID-19 disease. He has led several studies, focused on adapting and validating newer technologies (NGS, RNA-seq, OGM, etc) in CLIA laboratories by establishing PLA & Z-codes and reimbursement. He has authored more than 90+ peer-reviewed publications and serves on multiple CAP committees and scientific advisory boards for numerous profit and non-profit organizations.


 Speaker Profile

Ph.D., VP, Translational Medicine, Blueprint Medicines

Biography
Dr. Miller is currently Vice President of Translation Medicine at Blueprint Medicines, a Cambridge-based company focused on oncology precision medicine. He earned his Ph.D. in Biology at Caltech where he studied the structure, biochemistry and enzymology of the Type II Ca2+/calmodulin-dependent protein kinase. Following a postdoctoral fellowship at UC Berkely he moved to industry where over 30 years he has been involved in the drug discovery/development process from new target identification/validation, lead optimization and clinical development through registration. Dr. Miller and his groups have contributed to 27 INDs and 9 approved NDAs/BLAs that have provided new treatment options to patients both in the oncology and non-oncology setting.


 Speaker Profile

PHARM.D., Oncology Service Line Executive, Sutter Health

Biography
Jennifer Strickland-Reddy is an Oncology Pharmacist and has 16 years of oncology experience, five of those years in progressive leadership roles. Jennifer’s oncology experience includes ambulatory & inpatient, ICU, BMT, Infusion and oncology clinic settings. She currently works as the Oncology Service Line Executive for Sutter. Past work includes design and implementation of ambulatory business models, clinical mid-level patient care and oncology clinical pathways within health systems. She has presented and published her work nationally in cell research, oncology pharmacy and regulatory guidelines.


 Speaker Profile

M.D., Ph.D., FACP, FACMG, CMO, Natera Inc.

Biography
Dr. Paul R. Billings is a board-certified internist and clinical geneticist, who also holds a PhD in Immunology, from Harvard University. He worked there with Dr. Baruj Benacerraf, who subsequently received the Nobel Prize in Medicine. In 2018, Dr. Billings became the Chief Medical Officer and Senior Vice President for Medical Affairs at Natera, Inc., a global leader in human genetic testing. Dr Billings recently has been a Partner in the diagnostic medicine consultancy, the Bethesda Group, and the Managing Director of the Bethesda Group Fund. He is Chairman of PlumCare, LLc and Synergenz Biosciences Limited. He has held academic and research appointments at Harvard University, UC San Francisco, Stanford University and UC Berkeley. He co-founded the stem cell company, CBR Systems, was a Director at Ancestry.com and Signature Genomics Inc, and is co-founder and senior advisor of Fabric Genomics, Inc., a leading genome informatics firm. Until 2018, Dr. Billings was the Chairman of Biological Dynamics, a revolutionary molecular measurement platform based in San Diego, CA.


 Speaker Profile

Ph.D., Co-founder and CEO, Strata Oncology

Biography
Dan Rhodes is a scientist and entrepreneur focused on precision medicine in oncology. He co-founded Strata Oncology, a venture-backed precision oncology company committed to acceler-ating the impact of precision medicine for patients with cancer. Previously, Dan was VP of Oncology for Thermo Fisher Scientific (Life Technologies) where he oversaw the development of cancer sequencing products and pharma companion diagnostic partnerships. Prior to that, Dan was co-founder and CEO of Compendia Bioscience, a University of Michigan spin-off formed to commercialize his thesis project, Oncomine, a cancer genome data-mining platform. Dan has co-authored 40+ publications and is a co-inventor on 10 patents, including the discov-ery of gene fusions as a genetic cause of prostate cancer. In 2019, Dan was named Ernst & Young Entrepreneur of the Year for the Midwest region. Dan served on the oversight committee for the Michigan Translational Research and Commercialization (MTRAC) Program and on multi-ple advisory boards.